TY - JOUR
T1 - Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation
AU - Nawa, Y.
AU - Takenaka, K.
AU - Shinagawa, K.
AU - Deguchi, S.
AU - Matsumura, N.
AU - Koyama, S.
AU - Hiramatsu, Y.
AU - Omoto, E.
AU - Yoshino, T.
AU - Harada, M.
PY - 1999/6/2
Y1 - 1999/6/2
N2 - CD56+ angiocentric lymphoma has currently been recognized as a distinct clinical entity which is the prototype of the putative NK cell lymphomas. A 16-year-old Japanese girl with advanced CD56+ angiocentric lymphoma received high-dose chemotherapy supported with syngeneic peripheral blood stem cell transplantation (PBSCT). Prior to syngeneic PBSCT, she received six cycles of conventional chemotherapy before transplantation, resulting in a partial response. PBSC were mobilized with granulocyte colony-stimulating factor (G-CSF) and collected from her identical twin. High-dose cyclophosphamide, MCNU, etoposide, and carboplatin were used for pretransplant conditioning. Syngeneic PBSCT was well tolerated. She achieved complete remission and is now surviving in continuous complete remission for more than 30 months after syngeneic PBSCT. Thus, marrow-ablative chemotherapy facilitated by autologous or allogeneic PBSCT should be considered as part of the primary therapy for poor prognosis NK cell lymphomas.
AB - CD56+ angiocentric lymphoma has currently been recognized as a distinct clinical entity which is the prototype of the putative NK cell lymphomas. A 16-year-old Japanese girl with advanced CD56+ angiocentric lymphoma received high-dose chemotherapy supported with syngeneic peripheral blood stem cell transplantation (PBSCT). Prior to syngeneic PBSCT, she received six cycles of conventional chemotherapy before transplantation, resulting in a partial response. PBSC were mobilized with granulocyte colony-stimulating factor (G-CSF) and collected from her identical twin. High-dose cyclophosphamide, MCNU, etoposide, and carboplatin were used for pretransplant conditioning. Syngeneic PBSCT was well tolerated. She achieved complete remission and is now surviving in continuous complete remission for more than 30 months after syngeneic PBSCT. Thus, marrow-ablative chemotherapy facilitated by autologous or allogeneic PBSCT should be considered as part of the primary therapy for poor prognosis NK cell lymphomas.
KW - Granulocyte colony-stimulating factor
KW - High-dose chemotherapy
KW - Natural killer cell lymphoma
KW - Peripheral blood stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=0033516274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033516274&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1701803
DO - 10.1038/sj.bmt.1701803
M3 - Article
C2 - 10414923
AN - SCOPUS:0033516274
SN - 0268-3369
VL - 23
SP - 1321
EP - 1322
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 12
ER -